Chemotherapy-induced nausea and vomiting

incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance)

Lisa Kottschade, Paul Novotny, Alan Lyss, Miroslaw Mazurczak, Charles Lawrence Loprinzi, Debra Barton

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Despite newer agents, chemotherapy-induced nausea and vomiting (CINV) continues to remain a distressing side effect to a proportion of patients undergoing systemic anti-cancer therapy. Methods: We recently performed an unplanned secondary analysis on a previously reported negative phase III trial (N08C3) looking at the efficacy of gabapentin/placebo in combination with dexamethasone and a 5HT3 receptor antagonist in the prevention of CINV for 413 patients undergoing regimens with highly emetogenic chemotherapy (HEC). In the current study, we attempted to better understand the higher than expected rate of overall patient satisfaction, despite a low complete response rate in both arms. Additionally, we looked at patient variables and their relationship to rates of CINV. Results: Approximately one third of patients experienced more than mild nausea and reported scores on the Functional Living Index–Emesis that indicated interference with activities. Thirty-five percent reported nausea greater than 2.5 on a scale of 0 to 10 (0 being none), 19 % reported at least one emetic episode, and 49 % reported taking rescue medication. Nausea and vomiting on day 1, cisplatin therapy, and history of motion sickness significantly predicted delayed CINV. Age, combination chemotherapy (HEC with moderately emetogenic), and getting treatment for breast cancer predicted CINV on day 1. Discussion: These data confirm previous reports that subgroups of patients may be more prone to acute and delayed CINV. Future CINV study design may benefit from a more individualized approach to CINV management, targeting those patients who are truly at risk for CINV despite continued drug development efforts.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalSupportive Care in Cancer
DOIs
StateAccepted/In press - Jan 15 2016

Fingerprint

Nausea
Vomiting
Drug Therapy
Incidence
Direction compound
Motion Sickness
Emetics
Combination Drug Therapy
Patient Satisfaction
Dexamethasone
Cisplatin
Therapeutics
Placebos
Breast Neoplasms

Keywords

  • Characteristics
  • Chemotherapy-induced nausea and vomiting
  • Delayed nausea and vomiting
  • Incidence
  • Oncology

ASJC Scopus subject areas

  • Oncology

Cite this

Chemotherapy-induced nausea and vomiting : incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance). / Kottschade, Lisa; Novotny, Paul; Lyss, Alan; Mazurczak, Miroslaw; Loprinzi, Charles Lawrence; Barton, Debra.

In: Supportive Care in Cancer, 15.01.2016, p. 1-7.

Research output: Contribution to journalArticle

@article{18f1b9f5837a4fb4ad85fcff010bbfa4,
title = "Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance)",
abstract = "Background: Despite newer agents, chemotherapy-induced nausea and vomiting (CINV) continues to remain a distressing side effect to a proportion of patients undergoing systemic anti-cancer therapy. Methods: We recently performed an unplanned secondary analysis on a previously reported negative phase III trial (N08C3) looking at the efficacy of gabapentin/placebo in combination with dexamethasone and a 5HT3 receptor antagonist in the prevention of CINV for 413 patients undergoing regimens with highly emetogenic chemotherapy (HEC). In the current study, we attempted to better understand the higher than expected rate of overall patient satisfaction, despite a low complete response rate in both arms. Additionally, we looked at patient variables and their relationship to rates of CINV. Results: Approximately one third of patients experienced more than mild nausea and reported scores on the Functional Living Index–Emesis that indicated interference with activities. Thirty-five percent reported nausea greater than 2.5 on a scale of 0 to 10 (0 being none), 19 {\%} reported at least one emetic episode, and 49 {\%} reported taking rescue medication. Nausea and vomiting on day 1, cisplatin therapy, and history of motion sickness significantly predicted delayed CINV. Age, combination chemotherapy (HEC with moderately emetogenic), and getting treatment for breast cancer predicted CINV on day 1. Discussion: These data confirm previous reports that subgroups of patients may be more prone to acute and delayed CINV. Future CINV study design may benefit from a more individualized approach to CINV management, targeting those patients who are truly at risk for CINV despite continued drug development efforts.",
keywords = "Characteristics, Chemotherapy-induced nausea and vomiting, Delayed nausea and vomiting, Incidence, Oncology",
author = "Lisa Kottschade and Paul Novotny and Alan Lyss and Miroslaw Mazurczak and Loprinzi, {Charles Lawrence} and Debra Barton",
year = "2016",
month = "1",
day = "15",
doi = "10.1007/s00520-016-3080-y",
language = "English (US)",
pages = "1--7",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Chemotherapy-induced nausea and vomiting

T2 - incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance)

AU - Kottschade, Lisa

AU - Novotny, Paul

AU - Lyss, Alan

AU - Mazurczak, Miroslaw

AU - Loprinzi, Charles Lawrence

AU - Barton, Debra

PY - 2016/1/15

Y1 - 2016/1/15

N2 - Background: Despite newer agents, chemotherapy-induced nausea and vomiting (CINV) continues to remain a distressing side effect to a proportion of patients undergoing systemic anti-cancer therapy. Methods: We recently performed an unplanned secondary analysis on a previously reported negative phase III trial (N08C3) looking at the efficacy of gabapentin/placebo in combination with dexamethasone and a 5HT3 receptor antagonist in the prevention of CINV for 413 patients undergoing regimens with highly emetogenic chemotherapy (HEC). In the current study, we attempted to better understand the higher than expected rate of overall patient satisfaction, despite a low complete response rate in both arms. Additionally, we looked at patient variables and their relationship to rates of CINV. Results: Approximately one third of patients experienced more than mild nausea and reported scores on the Functional Living Index–Emesis that indicated interference with activities. Thirty-five percent reported nausea greater than 2.5 on a scale of 0 to 10 (0 being none), 19 % reported at least one emetic episode, and 49 % reported taking rescue medication. Nausea and vomiting on day 1, cisplatin therapy, and history of motion sickness significantly predicted delayed CINV. Age, combination chemotherapy (HEC with moderately emetogenic), and getting treatment for breast cancer predicted CINV on day 1. Discussion: These data confirm previous reports that subgroups of patients may be more prone to acute and delayed CINV. Future CINV study design may benefit from a more individualized approach to CINV management, targeting those patients who are truly at risk for CINV despite continued drug development efforts.

AB - Background: Despite newer agents, chemotherapy-induced nausea and vomiting (CINV) continues to remain a distressing side effect to a proportion of patients undergoing systemic anti-cancer therapy. Methods: We recently performed an unplanned secondary analysis on a previously reported negative phase III trial (N08C3) looking at the efficacy of gabapentin/placebo in combination with dexamethasone and a 5HT3 receptor antagonist in the prevention of CINV for 413 patients undergoing regimens with highly emetogenic chemotherapy (HEC). In the current study, we attempted to better understand the higher than expected rate of overall patient satisfaction, despite a low complete response rate in both arms. Additionally, we looked at patient variables and their relationship to rates of CINV. Results: Approximately one third of patients experienced more than mild nausea and reported scores on the Functional Living Index–Emesis that indicated interference with activities. Thirty-five percent reported nausea greater than 2.5 on a scale of 0 to 10 (0 being none), 19 % reported at least one emetic episode, and 49 % reported taking rescue medication. Nausea and vomiting on day 1, cisplatin therapy, and history of motion sickness significantly predicted delayed CINV. Age, combination chemotherapy (HEC with moderately emetogenic), and getting treatment for breast cancer predicted CINV on day 1. Discussion: These data confirm previous reports that subgroups of patients may be more prone to acute and delayed CINV. Future CINV study design may benefit from a more individualized approach to CINV management, targeting those patients who are truly at risk for CINV despite continued drug development efforts.

KW - Characteristics

KW - Chemotherapy-induced nausea and vomiting

KW - Delayed nausea and vomiting

KW - Incidence

KW - Oncology

UR - http://www.scopus.com/inward/record.url?scp=84954425357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954425357&partnerID=8YFLogxK

U2 - 10.1007/s00520-016-3080-y

DO - 10.1007/s00520-016-3080-y

M3 - Article

SP - 1

EP - 7

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

ER -